Cumberland Pharmaceuticals Reports 11.6% Fourth Quarter 2024 Revenue Growth

Core Insights - Cumberland Pharmaceuticals Inc. reported a net revenue of $10.4 million for Q4 2024, marking an 11.6$38 million [1][9] - The company ended 2024 with total assets of $76 million, including$18 million in cash and $53 million in liabilities [2][12] - CEO A.J. Kazimi highlighted 2024 as a transformative year with expanded product labeling, key FDA designations, and new study publications [3] Financial Performance - For the full year 2024, net revenues were$38 million, with significant contributions from Kristalose® ($15.3 million), Sancuso® ($9 million), Vibativ® ($7.2 million), and Caldolor® ($5 million) [9] - Total operating expenses for 2024 were $44 million, resulting in a net loss of approximately$6.4 million for the year [9][11] - The adjusted loss for the year was $1 million, excluding certain costs related to product acquisitions [11] Product Developments - The FDA granted Orphan Drug and Rare Pediatric Disease designations for ifetroban, aimed at treating cardiomyopathy in Duchenne muscular dystrophy [3] - New research published demonstrated Caldolor's safety and healthcare resource advantages over ketorolac in both adult and pediatric populations [4] - A simplified dosing regimen for Acetadote® was approved by the FDA, enhancing the efficiency of administration [6] Clinical Trials and Studies - Cumberland made significant progress in Phase II clinical trials for ifetroban, closing studies in Duchenne muscular dystrophy and nearing completion in systemic sclerosis and pulmonary fibrosis [8] - The company provided 3.9 million doses of FDA-approved products to patients in 2024 and reported no product recalls [7] Market Expansion - Vibativ® received approval in China, expanding Cumberland's international business, alongside shipments to Saudi Arabia [10]